### Halo's Biotech Acquisition: Transforming Cancer Treatment Delivery

Halo aims to revolutionize cancer treatment with quick subcutaneous drug delivery, enhancing patient care and healthcare efficiency.

### Transforming Cancer Treatment: Halo's Innovative Drug Delivery and Strategic Acquisition
* 💊 Halo aims to revolutionize cancer treatment by **improving chemotherapy delivery methods**, making them **quicker and more accessible** for patients.
* 🏢 Based in San Diego, Halo has developed a drug delivery platform that allows for subcutaneous injections, significantly **reducing the time spent on intravenous therapies from hours to just 3 to 5 minutes**.
* 🏥 This advancement means patients can receive treatment in a doctor's office or even at home, **alleviating the burden of hospital visits and travel for caregivers**.
* 💰 Halo anticipates generating approximately **$1 billion in revenue** this year, with an EBITDA of **$600 million**, showcasing its potential for **growth and cash flow generation**.
* 🔗 The company plans to enhance its capabilities by acquiring Evotec, which specializes in **drug discovery and manufacturing**, aligning with Halo's **licensing business model**.
* 📈 Evotec's continuous manufacturing process aims to deliver **higher quality drugs at lower costs**, creating a synergistic partnership that can **drive revenue growth**.
* 🤝 With over 500 partners, Halo's acquisition of Evotec is expected to **facilitate cross-selling opportunities and attract new partners**, positioning the company for **long-term success**.
* 📊 Despite recent market challenges, Halo believes that Evotec is well-positioned for growth, and the combined entity will offer **above-average gross margins**, making it an **attractive investment for shareholders**.

Halozyme CEO: Evotec Is Poised for Growth

Welcome to the Bloomberg Technology YouTube channel. Subscribe for original series and mini-docs on game-changing technologies, profiles on innovators, live conversations with experts, and breaking technology news & analysis from Bloomberg TV.

Bloomberg Technology

Halo aims to improve cancer treatment by simplifying chemotherapy delivery.

Halo is a biotech company with a subcutaneous drug delivery platform.

The platform transforms intravenous therapies into subcutaneous injections.

This improves patient experience and reduces healthcare system costs.

Halo projects significant revenue and EBITDA.

Halo's business model is licensing technology, similar to Evotec's drug discovery.

Evotec's mission aligns with Halo's, focusing on more effective medicines.

Evotec's manufacturing capabilities offer high quality and low cost.

The acquisition creates a strong combination of revenue growth and EBIT contribution.

Addressing Market Concerns and Investor Confidence

Evotec's stock price has declined significantly.

Halo conducted customer interviews to assess Evotec's platforms.

Halo believes Evotec is poised for growth.

The acquisition creates a leading pharma services company with high gross margins.

Timing and Strategic Fit of the Acquisition

Discussion on the timing of the M&A and potential political influences.

Halo had been searching for the right acquisition for several years.

Evotec met Halo's strict criteria for revenue and partner growth.

Growth opportunities through cross-selling and attracting new partners.

Growth will come from internal expansion and new partnerships.